Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

Abstract: The present invention relates to compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract: The present invention relates to compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

Abstract: The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

Abstract: An output signal adjustment system includes a signal adjustment unit, a reference slope generating unit, a slope detecting unit, a voltage-to-current conversion unit, and a control unit. The slope detecting unit compares the slope of the rising and falling edges of the output signal of the reference slope generating unit with that of the signal adjustment unit and outputs a voltage signal. The voltage-to-current conversion unit converts the voltage signal into a current signal. Based on the current signal, the control unit outputs a control signal for controlling the adjustment of the signal adjustment unit to the slope of the rising and falling edges of the output signal. The output signal adjustment system can automatically adjust the slope of the rising and falling edges of the output signal, so that the output signal is insensitive to the packaging, the printed circuit board, the transmission line and other sender loads.

Abstract: A frequency detector includes a multi-phase clock generation unit, a sampling unit connected to the multi-phase clock generation unit and a digital logic unit connected to the sampling unit. An inputted single-phase clock is received by the multi-phase clock generation unit and transformed into a multi-phase clock. Inputted random data are received by the sampling unit and sampled by the multi-phase clock. Each data bit of the random data is divided into several sampling intervals according to a phase number of the multi-phase clock. The digital logic unit analyzes sampling values logically, judges the corresponding sampling interval of each sampling value and outputs signals for indicating that a frequency of the random data is higher or lower than the frequency of the single-phase clock based on differences in the corresponding sampling intervals of the sampling values at two adjacent times. A method for detecting frequencies is further provided.

Abstract: A frequency multiplier system, for outputting a single phase clock of N multiplied frequency after processing an inputted clock, N?2, includes a frequency divider receiving the inputted clock, an interpolator connected with the frequency divider, a phase equalizer connected with the interpolator, and a combinational logic circuit connected with the phase equalizer, wherein the frequency divider outputs an orthogonal clock having a two-phases frequency that is a half of the inputted clock to the interpolator, the interpolator outputs a 2N-phases clock to the phase equalizer, the phase equalizer homogenizes a phase skew of the 2N-phases clock, the combinational logic circuit synthesizes the homogenized 2N-phases clock into a single phase clock of N multiplied frequency. And a method of multiplying frequency is provided. The present invention does not need feedback circuits, and therefore is stable and fast-speed, saves area, and reduces energy consumption.

Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.